Peer-Reviewed Journal Details
Mandatory Fields
O'Hanlon, D. M., Kerin, M. J., Kent, P., Skehill, R., Grimes, H., Maher, D., Given, H. F.
1995
February
Journal Of The American College Of Surgeons
A prospective evaluation of CA15-3 in Stage 1 Breast Carcinoma
Published
()
Optional Fields
MONOCLONAL-ANTIBODY METASTATIC DISEASE FOLLOW-UP CANCER TUMORS DF3
180
2
210
212
BACKGROUND: Carcinoma of the breast is characterized by a variable course with prognosis dependent on disease stage at presentation. Paradoxically, some patients with early malignancy demonstrate disease progression within a short time. The role of tumor markers in the management of carcinoma of the breast is controversial. While CA15-3 is the most widely used tumor marker in carcinoma of the breast, its role in the management of patients with early disease is controversial.STUDY DESIGN: Since 1986, all patients presenting to our unit with carcinoma of the breast have had serial CA15-3 levels measured. This study evaluates the role of serial CA15-3 levels in the management of a consecutive series of 168 patients with Stage I disease at presentation.RESULTS: The mean preoperative CA15-3 levels at presentation were significantly elevated in patients with Stage I disease compared with patients with benign disease. Sixteen patients had either locoregional (five patients) or metastatic recurrence (11 patients). CA15-3 levels were not elevated in patients with locoregional disease and were significantly elevated in patients with bony metastases and gave a mean lead time of 6.3 months over bone scintigraphy.CONCLUSIONS: Serial CA15-3 measurements are an efficient and cost-effective method of monitoring disease progression and have advantages over conventional investigations in patients with early carcinoma of the breast.
Grant Details
Publication Themes